慢性乙型肝炎肝纤维化逆转评估方法的探讨  

A discussion of the methods for the assessment of chronic hepatitis B-related liver fibrosis regression

作　　者：孙亚朦[1] 吴晓宁[1] 周家玲 尤红[1] 

机构地区：[1]首都医科大学附属北京友谊医院肝病中心,北京100050

出　　处：《中华肝脏病杂志》2016年第7期552-554,共3页Chinese Journal of Hepatology

摘　　要：抗病毒治疗可以逆转乙型肝炎肝纤维化和早期肝硬化，但对纤维化逆转的评估目前仍存在争议。肝穿刺活组织检查方面，作为“金标准”仍存在局限性。无创诊断方面，瞬时弹性成像干扰因素较多，血清学指标目前临床研究证据较少，因此，用于评估纤维化逆转仍需要更多临床研究证据支持。l Antiviral therapy could reverse hepatitis B-related liver fibrosis and early-stage cirrhosis. However, the assessment of fibrosis regression remains controversial. As the gold standard for assessment, liver biopsy has its own limitations. In terms of non-invasive assessment, there are many interfering factors for transient elastography and less clinical evidence for the use of serum markers. Therefore, further evidence from clinical studies is still needed to determine the role of non-invasive methods in evaluating fibrosis regression.

关 键 词：肝炎 乙型 慢性 肝硬化 逆转 肝穿刺活组织检查 肝脏弹性 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]